anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:A cephem compound or penam compound having a partial structure of formula I (R<1> is amino group or hydroxyl group which may be substituted; R<2> is amino group, hydroxyl group or a group convertible thereinto; R<3> is methoxyl or a group convertible into the methoxyl group; R<8> is H or halogen) or a penam compound having a partial structure of formula II, etc. EXAMPLE:Sodium 7beta-(2-aminothiazol-4-ylglycylamido)cephalosporanate. USE:An antimicrobial substance, useful for infectious diseases in respiratory organs and urinary tracts, and having antimicrobial action widely on Gram-positive and Gram-negative bacteria. PROCESS:A cephem or penam compound having a partial structure of formula IIIis reacted with a compound of formula IV in a solvent, e.g. acetone, usually under cooling or at room temperature for several minutes - several hours, and if necessary the protecting groups are removed or (and) groups are converted to give the aimed cephem or penam compound having the partial structure of formula I . A base, e.g. pyridine, is added to the solvent to promote advantageously the reaction.
Study approval was obtained from Institutional Review Board (IRB) of Samsung medical center, and written informed consent was obtained from all participants.

The required sample size was determined by power analysis on the basis of a previous study. The primary outcome was pain intensity in the posterior neck and upper back after TPI using verbal numerical rating scale (VNRS). The standard deviation of VNRS was assumed to be 20. Power calculations indicated that detecting 20 points difference in VNRS between the two groups (with α = 0.05 and β = 0.1) would require a sample of 29 subjects for each group. To account for dropouts, 33 subjects were recruited for each group.

Group L received TPI with a 3.2 ml of a 1:1 mixture of 1% lidocaine and 0.9% normal saline. Group H received TPI with the same volume of solution supplemented with hyaluronidase (H-LASE®, 1500 iu, L\&H Pharm., Seoul, Korea) 600 iu/ml. The investigators monitored vital sign and any signs of complications such as bleeding, hematoma, allergic reactions for 30 minutes. Treatment efficacy was evaluated by one of the authors (J.W.C.) using VNRS. To reduce bias, this evaluator and the participants were not informed of the assigned group.

Patients' characteristics such as age, height, weight, BMI and pretreatment neck disability index (NDI) and brief pain inventory (BPI) were analyzed by independent t-test. The sex distribution was analyzed by the chi-square test. P values were corrected by Bonferroni's method. Pretreatment VNRS and the duration of pain were evaluated by the Wilcoxon two-sample test. Repeated measures ANOVA was used to compare changes in the VNRS over time between the two groups. Pre- and post-TPI changes in NDI and BPI were compared between the two groups with the Wilcoxon signed rank test and the independent t-test, respectively. All analyses were performed with SPSS 18.0 (SPSS Inc., Chicago, IL, USA) statistical software. Significance was assumed for P values of less than 0.05.
The present invention provides methods and apparatuses for constructing observed data from a Compton camera in order to provide a three-dimensional image of a radiopharmaceutical source distribution within a patient. No intermediate two-dimensional images are formed. Observed data may be analyzed by a processor in order to construct a three-dimensional image representing the source distribution. An idealized mathematical model may express the observed Compton camera data in terms of an integral over the source distribution. An exact analytic inversion is then found for this idealized model. The new analytic solutions arise from a generalization of the integral equation used to model the Compton camera. The kernel of the integral equation is modified by the introduction of an index p that describes the effect of source distance from the camera.
<P>PROBLEM TO BE SOLVED: To provide effective means for inducing immune tolerance mediated by antigen-specific T cells.  <P>SOLUTION: An immune tolerance inducer contains an apoptosis induction product of a cell having an antigen bound to the cell surface as an active ingredient. A prophylactic agent of autoimmune diseases contains the apoptosis induction product as an active ingredient. A prophylactic agent for allergy contains the apoptosis induction product as an active ingredient. In a method of preparing the immune tolerance inducer, the prophylactic agent for autoimmune diseases or the prophylactic agent for allergy includes a step of culturing the cell having the antigen bound to the cell surface and a step of inducing apoptosis of the cultured cell to prepare the apoptosis induction product of the cell.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Esophageal squamous cell carcinoma (ESCC) is one of the most fatal cancers worldwide. Most ESCC patients are diagnosed at an advanced stage; however, current research on in vivo animal models accurately reflecting their clinical presentation is lacking. Alcohol consumption is a major risk factor for ESCC and has been used in several disease models for disease induction. In this study, we used 4-nitroquinoline-1-oxide in combination with ethanol to induce an in vivo ESCC mouse model. Esophageal tissues were stained with hematoxylin and eosin for histopathological examination and lesion scoring. In cellular experiments, cell adhesion and migration invasion ability were observed using phalloidin staining, cell scratch and transwell assays, respectively, and the expression of epithelial-mesenchymal transition-related markers was detected using quantitative reverse transcription polymerase chain reaction and western blotting. The results showed that ethanol-exposed mice lost more weight and had an increased number of esophageal nodules. Histological examination revealed that the lesion scores of the ethanol-exposed esophageal samples were significantly higher than those of the unexposed esophageal samples. Furthermore, ethanol-exposed esophageal cancer samples had more severe lesions with infiltration of tumor cells into the muscularis propria. In vitro cellular experiments showed that ethanol exposure induced cytoskeletal microfilament formation, promoted cell migration invasion elevated the expression of N-cadherin and Snail, and decreased the expression of E-cadherin. In conclusion, ethanol exposure exacerbates ESCC, promotes tumor cell infiltration into the muscularis propria, and could be an effective agent for establishing innovative models of invasive carcinoma.
Cochlear implant (CI) is currently the vital technological device for assisting deaf patients in hearing sounds and greatly enhances their sound listening appreciation. Unfortunately, it performs poorly for music listening because of the insufficient number of electrodes and inaccurate identification of music features. Therefore, this study applied source separation technology with a self-adjustment function to enhance the music listening benefits for CI users. In the objective analysis method, this study showed that the results of the source-to-distortion, source-to-interference, and source-to-artifact ratios were 4.88, 5.92, and 15.28 dB, respectively, and significantly better than the Demucs baseline model. For the subjective analysis method, it scored higher than the traditional baseline method VIR6 (vocal to instrument ratio, 6 dB) by approximately 28.1 and 26.4 (out of 100) in the multi-stimulus test with hidden reference and anchor test, respectively. The experimental results showed that the proposed method can benefit CI users in identifying music in a live concert, and the personal self-fitting signal separation method had better results than any other default baselines (vocal to instrument ratio of 6 dB or vocal to instrument ratio of 0 dB) did. This finding suggests that the proposed system is a potential method for enhancing the music listening benefits for CI users.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to therapy, cardiology. hematology, and can be used for managing patients with chronic lymphatic leukemia in a polychemotherapy (PCT) according to a FCR scheme aimed at preventing cardiotoxicity. Perform echocardiography EchoCG, global longitudinal strain GLS evaluation and troponin level determination in biochemical blood analysis. Prior to prescribing polychemotherapy FCC according to a FCR scheme, patients underwent 3D-EchoCG and speckle tracking EchoCG with determination of GLS. High-sensitivity troponin T hscTnT is determined in biochemical blood analysis. If the ejection fraction EF of the left ventricular is below normal, then prior to PCT, cardioprotective therapy is prescribed with one preparation. After the PCT course similar examinations and patient's examination by the cardiologist is performed: if the cardiotoxicity is diagnosed, a second cardioprotective preparation is added to the treatment. Similar examinations are performed and the patient is examined by a cardiologist after each course of PCT. In the absence of cardiotoxicity after a PCT course, similar examinations and patient's examination by a cardiologist is performed once in 3 months. For the patients with the initial normal EF of the left ventricle, similar studies are conducted after 3 PCT courses: with reduction GLS>15 % of the initial value and an increase in the hscTnT level, one cardioprotective therapy is added to the therapy, similar examinations are performed and patient is examined by cardiologist once in 3 months. If GLS is relative reduced by ≤15 % after 3 courses of PCT, stress EchoCG with dobutamine is used to determine contractile reserve by GLS and if it is absent, 3D-EchoCG, speckle-tracking EchoCG with determination of GLS are performed once in 3 months and stress-EchoCG after PCT is completed. If observing the GLS reduction of ≤15 % after 3 PCT courses and the presence of the contractile GLS reserve in the stress-EchoCG patient, performing 3D-EchoCG, speckle-tracking EchoCG with GLS determination after PCT completion.EFFECT: method enables administering patients with chronic lymphatic leukemia in the PCT according to the FCR scheme to prevent cardiotoxicity by a clear algorithm for interpreting results obtained during monitoring and monitoring the onset of cardiotoxicity in the patients in FCR chemotherapy.1 cl, 5 ex
<P>PROBLEM TO BE SOLVED: To provide a method for easily producing propolis powder excellent in fluidity.  <P>SOLUTION: The method for producing propolis powder comprises a diluting process where propolis is diluted with water to prepare diluted solution, and a pulverizing process where the diluted solution is pulverized. A propolis extracted solution comprises the one extracted from propolis raw material with alcohol or hydroalcohol having an alcohol concentration of ≥60 vol.%. The diluting process comprises a binder-forming treatment for forming binder facilitating pulverization in the diluted solution. The binder-forming treatment comprises at least one kind selected from alkali treatment, organic-matter addition treatment and calcium addition treatment.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Consecutive patients with severe aortic stenosis with indication to aortic balloon valvuloplasty will be enrolled. An ad hoc informed consent for the procedure will be obtained from all patients.

This is a prospective observational study. The Investigators will include patients where aortic ballloon valvuloplasty is attempted by radial access and without temporary pacemaker implantation. The aim is to register and monitor the effectiveness and safety of this approach. Details regarding management of radial access and pacing with 0.035 wire can be found in the references reported below. The primary endpoint will be the 30-day occurence of minor and major vascular complications according VARC 2 classification. The safety endpoint will be the absence of intra- or periprocedural major complications in transradial balloon aortic valvuloplasty, namely balloon entrapment or compartment syndrome requiring surgical intervention.

The feasibility endpoint will be a procedural success rate ≥90%. The efficacy endpoint will be a reduction of the mean invasive gradient \>30%. At baseline, Handgrip strength test will be performed and angiography of the instrumented arm will be performed at the beginning and at the end of the procedure. All patients will be prospectively followed-up for at least 30 days and all adverse events will be recorded. All patients will be assessed also for frailty according the clinical frailty scale (CFS). During the 30-day follow-up visit two independent blinded operators will evaluate radial artery patency by ultrasonography and perform handgrip strength test in in both arms in all patients.
Cytarabine: subcutaneously twice daily from day 1 - 10. Sorafenib: Days 2-28; at the dose level assigned at registration. Sorafenib will be given orally twice daily.
It is intended to provide a compound represented by the following general formula (1) wherein X is selected from heteroaryl, etc.; Yand Yare selected from -N=, etc.;Yand Yare selected from -CH=, etc.; A is selected from sulfamide, etc.; Ris selected from hydrogen, etc.; and R is selected from Calkyl, etc., or a pharmaceutically acceptable salt thereof. Because of having a sufficiently high antitumor activity, this compound or its salt is useful as a remedy for cell proliferative diseases, in particular, cancer. It is also intended to provide a medicinal composition which contains the above-described compound or its salt as the active ingredient
BACKGROUND: Heart failure is a chronic and progressive disease where the heart muscle is unable to pump enough blood and oxygen to meet the body's needs. Oxidative stress and inflammation are key elements in the development and progression of heart failure. Astaxanthin, a carotenoid, has strong anti-inflammatory and antioxidant effects that may protect the cardiovascular system. A study will evaluate the effect of astaxanthin supplementation on inflammatory status, oxidative stress, lipid profile, uric acid levels, endothelial function, quality of life, and disease symptoms in people with heart failure.
METHODS: The current study is a double-blind controlled randomized clinical trial for 8 weeks, in which people with heart failure were randomly assigned to two groups: intervention (one capsule containing 20 mg of astaxanthin per day, n = 40) and placebo (one capsule containing 20 mg of maltodextrin per day, n = 40) will be divided. At the beginning and end of the intervention, uric acid, lipid profile, oxidative stress indices, inflammatory markers, blood pressure, nitric oxide, and anthropometric factors will be measured, and questionnaires measuring quality of life, fatigue intensity, shortness of breath, and appetite will be completed. SPSS version 22 software will be used for statistical analysis.
DISCUSSION: There is a growing global interest in natural and functional food products. This RCT contributes to the expanding body of research on the potential benefits of astaxanthin in heart failure patients, including its antioxidant, lipid-lowering, and anti-inflammatory effects.
TRIAL REGISTRATION: Iranian Registry of Clinical Trials IRCT20200429047235N3. Registered on 26 March 2024.
Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.
Standard of care systemic therapy plus radiation. Radiation will start within 8 weeks of randomization and complete by day 84. Standard of care systemic therapy may continue in the absence of toxicities or other specific criteria per protocol.
The proposed study is a single arm feasibility study of a supportive care intervention. Phase is not applicable because this is not a drug trial. The study involves enrolling older adult non-metastatic cancer survivors between 1 month and 24 months after the completion of any definitive (e.g., curative intent) cancer treatment. The objective is to determine if a Community Health Worker (CHW)-led geriatric assessment and coaching intervention to assess geriatric syndromes is a feasible modality in community-dwelling older adult cancer survivors. The tailored assessment intervention (geriatric assessment and coaching) is hypothesized to potentially be a feasible process to monitor patients that would otherwise not access geriatric services after completing cancer treatment. Coping and social support are hypothesized mediators to the relationship between physical function and health outcomes (e.g., physical function, mental health), influenced by sociodemographic contextual factors. Implementation science concepts, such as acceptability and scalability will also be collected. The study CHW will perform the geriatric assessment and coaching components with each of the patients in the study. The assessment component of the bundle intervention involves screening for frailty and cognition, occurring prior to the coaching session. The CHW will conduct a more thorough geriatric assessment for polypharmacy, depression, symptom burden, and social support. In follow up visits after the geriatric assessment the CHW will deliver the coaching component (derived from the Problem Solving Coaching Model) to participants. Each of the intervention sessions will consist of 45-minute appointments with tailored feedback of the geriatric assessment domains, caregiver and family support, and navigation to additional palliative care resources at the study institution. The researchers developed the content in the tailored assessment intervention from preliminary work and thorough review of scientific literature.
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately 50% of total heart failure patients and is characterized by peripheral circulation, cardiac remodelling and comorbidities (such as advanced age, obesity, hypertension and diabetes) with limited treatment options. Chidamide (HBI-8000) is a domestically produced benzamide-based histone deacetylase isoform-selective inhibitor used for the treatment of relapsed refractory peripheral T-cell lymphomas. Based on our in vivo studies, we propose that HBI-8000 exerts its therapeutic effects by inhibiting myocardial fibrosis and myocardial hypertrophy in HFpEF patients. At the cellular level, we found that HBI-8000 inhibits AngII-induced proliferation and activation of CFs and downregulates the expression of fibrosis-related factors. In addition, we observed that the HFpEF group and AngII stimulation significantly increased the expression of TGF-β1 as well as phosphorylated p38MAPK, JNK and ERK, whereas the expression of the above factors was significantly reduced after HBI-8000 treatment. Activation of the TGF-β1/MAPK pathway promotes the development of fibrotic remodelling, and pretreatment with SB203580 (p38MAPK inhibitor) reverses this pathological change. In conclusion, our data suggest that HBI-8000 inhibits fibrosis by modulating the TGF-β1/MAPK pathway thereby improving HFpEF. Therefore, HBI-8000 may become a new hope for the treatment of HFpEF patients.
Minimally verbal children between 2.0 and 3.9 years with autism spectrum disorder (ASD) and who do not emit vocalizations, will be randomly assigned to the treatment group and will begin the stimulus-stimulus pairing (SSP) procedure. Subjects will be recorded by a vocal recorder at home by the parent/guardian at home or in the community setting.
Participants with L1 mCRPC and no HRR Gene alteration will receive combination of niraparib 200 mg or matching placebo and AA 1000 mg plus prednisone 10 mg. In the OLE phase participants earlier receiving the combination of niraparib and AAP may continue to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg and those receiving placebo and AAP may cross over depending on the outcome of study to receive open-label combination of niraparib 200 mg and AA 1000 mg plus prednisone 10 mg.
New antibiotic substances named substance No. 17927A 2  and substance No. 17927A 1  produced by cultivation of substances No. 17927A 2  and No. 17927A 1  -producing microorganisms belonging to the genus Streptomyces as well as pharmaceutically-acceptable salts thereof. They have broad antibacterial activities and also β-lactamase inhibitory action so that they show synergistic actions with known penicillins and cephalosporins.
PURPOSE:A cardiotonic agent, containing evodiamine present in a fruit of Evodia rutaecarpa Benth. of the family Rutaceae as an active constituent, having excellent contraction enhancing action on cardiac muscle, and useful as a remedy for various cardiac insufficiencies. CONSTITUTION:A cardiotonic agent containing evodiamine of the formula. The evodiamine of the formula can be prepared by separation and purification from a fruit of Evodia rutacecarpa Benth. of the family Rutaceae, and is found to have cardiotonic action with improved dosage dependence and to be usable as the cardiotonic agent. The amount for treatment is 0.1-1mg/kg/day for parenteral administration and 1-10mg/kg/day for oral administration. The agent is used in the form of a tablet, capsule or solution, etc. for the oral administration and a sterilized solution, e.g. liquid or suspension, for the parenteral administration.
This is a single-arm physiology study. Consenting patients undergoing neck dissection (ND) for cervical lymphadenectomy of level IV will undergo dissection of the ansa cervicalis nerves to the infrahyoid strap muscles. Per routine care, a large incision is made across the neck to provide surgeons access to the cervical lymph nodes for extirpation. During this dissection, the branch(es) of the ansa cervicalis nerve plexus descending from the loop of the plexus and innervating the infrahyoid strap muscles (the "common trunk") are dissected uni- or bilaterally. For this study, measurements and photos/videos of the common trunks will be taken. An electrode will be placed on one or both common trunks to stimulate infrahyoid muscles.
ANZEMET prolongs the QT interval in a dose dependent fashion. Torsade de Pointes has been reported during post-marketing experience. Avoid ANZEMET in patients with congenital long QT syndrome, hypomagnesemia, or hypokalemia. Hypokalemia and hypomagnesemia must be corrected prior to ANZEMET administration. Monitor these electrolytes after administration as clinically indicated. Use ECG monitoring in patients with congestive heart failure, bradycardia, renal impairment, and elderly patients (see CLINICAL PHARMACOLOGY).
Patients receive a mixture of Lactobacillus plantarum strain 299v, Bifidobacterium lactis probiotic supplement, and Lactobacillus acidophilus probiotic PO BID for 9 weeks. Treatment continues in the absence of unacceptable toxicity.
Evidence is provided for a new mechanism by which Wg signaling regulates the shape of the Wg protein gradient. High levels of Wg signaling induce expression of a protein with similarity to predicted pectin acetylesterases from plants and plant pathogens. We have called this gene Torero based on its loss-of-function mutant phenotype (Andalucian for dragonfly). When overexpressed Torero blocks Wg activity. Loss of Torero function leads to increased Wg activity by altering the shape of the Wg protein gradient. Torero activity is required in the embryo and the imaginal discs to limit Wg activity.